BEHIND THE DEAL: Why Medtronic And Qualcomm Are Teaming Up On Diabetes
This article was originally published in Clinica
Executive Summary
Diabetes might be Medtronic’s smallest business division in terms of revenue but its growth rates are far from stunted, having recorded the top-line increases of 6% for both the fourth fiscal quarter and full fiscal year 2016.
You may also be interested in...
Qualcomm: A New Kind Of Medical Device Company
The mobile-technology company is trying to corner the wireless needs of the health-care industry, and is pushing for adoption of value-based health-care models that would be dependent on more data-sharing to justify costs based on patient outcomes.
Could Alcon's CyPass Trouble Be Boon For Glaukos – Or Bust For MIGS?
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roche Dx' EMEA Head To Take Charge After Diggelmann Departs
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.